Inhibikase Therapeutics (IKT) Capital Leases (2022 - 2024)

Inhibikase Therapeutics (IKT) reported Capital Leases of $58330.0 for Q1 2024, down 67.25% year-over-year from $178110.0 in Q2 2023, and down 35.28% quarter-over-quarter from $90124.0 in Q4 2023.

Inhibikase Therapeutics (IKT) Capital Leases (2022 - 2024) Analysis & Trends

Inhibikase Therapeutics (IKT) has 3 years of Capital Leases data on file, last reported at $58330.0 in Q1 2024.

  • Capital Leases for Q1 2024 came in at $58330.0, down 67.25% year-over-year; the trailing twelve-month figure through Mar 2024 was $58330.0 (down 67.25% YoY), and the FY2023 annual result was $90124.0, down 56.13% from the prior year.
  • Capital Leases slipped to $58330.0 in Q1 2024 per IKT's latest filing, from $90124.0 in the prior quarter.
  • Over five years, Capital Leases peaked at $232020.0 in Q3 2022 and troughed at $58330.0 in Q1 2024.
  • A 3-year average of $147859.9 and a median of $149971.0 in 2023 frame the typical range for Capital Leases.
  • The sharpest annual moves came in 2023 and 2024: Capital Leases sank 47.84% in 2023, then sank 67.25% in 2024.
  • A 3-year view of Capital Leases shows it stood at $205451.0 in 2022, then tumbled by 56.13% to $90124.0 in 2023, then sank by 35.28% to $58330.0 in 2024.
  • Business Quant data shows IKT's Capital Leases at $58330.0 in Q1 2024, $90124.0 in Q4 2023, and $121013.0 in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn -
7 Psyence Biomedical 227.32 Bn 227.31 Bn -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn
9 Abivax 91.71 Bn 91.71 Bn -
10 Inhibikase Therapeutics 285.17 Mn 114.80 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2024 58,330.00
Dec 31, 2023 90,124.00
Sep 30, 2023 121,013.00
Jun 30, 2023 149,971.00
Mar 31, 2023 178,110.00
Dec 31, 2022 205,451.00
Sep 30, 2022 232,020.00